Cadrenal Therapeutics Secures Up to $8.8M Private Placement, Extending Cash Runway
CVKD sits 31% above its 52-week low of $2.55 on light trading volume (0.3× avg).
Summary
Cadrenal Therapeutics announced a private placement to raise up to $8.8 million, comprising $3 million upfront and $5.8 million from potential warrant exercises. This financing is critical as the company's last 10-Q reported a going concern warning and a cash runway only into October 2026. The proceeds are anticipated to extend the cash runway into Q1 2027, or into H2 2027 if all warrants are exercised. While necessary for continued operations, this offering represents significant potential dilution relative to the company's current market valuation. The offering is expected to close around July 1, 2026.
At the time of this announcement, CVKD was trading at $3.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $2.55 to $14.64. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.